Digital Tools, Employer Programs, and New ADA Guidance Are Changing How Type 2 Diabetes Is Managed

A new FDA‑cleared software tool gives insulin‑dosing advice based on continuous glucose monitor data, and a large employer’s digital education program shows promise for people with Type 2 diabetes [1][2]. At the same time, the American Diabetes Association (ADA) has issued its first scientific statement on diabetes technology in primary care, urging broader access to these tools [3].

Key takeaways

• An FDA‑cleared algorithm (MODI) uses continuous glucose monitor data to suggest insulin doses for people with Type 2 diabetes [1].
• A real‑world study of a digitally based diabetes self‑management education program found higher use of education services among participants, especially younger adults and those in metropolitan areas [2].
• The ADA’s new statement recommends that all people with diabetes have access to evidence‑based diabetes technologies and that primary‑care teams support their use [3].

FDA clearance for a CGM‑driven dosing tool

DreaMed Diabetes received 510(k) clearance from the U.S. Food and Drug Administration for its MODI platform [1]. MODI links continuous glucose monitor readings to an algorithm that recommends insulin doses for people who use injection regimens for Type 2 diabetes [1]. The clearance means the tool met the agency’s safety and effectiveness standards, allowing it to be marketed in the United States [1].

Employer‑driven digital education shows real‑world use

A large employer examined how its digitally based diabetes self‑management education and support (DSMES) program was used over two years [2]. The analysis looked at age, sex, subscriber status, metropolitan residence, and comorbidity scores [2]. People who accessed any DSMES during the study period were more likely to be younger, live in metropolitan areas, and have lower comorbidity scores [2]. The findings suggest that digital education can reach certain subgroups, but the study did not measure changes in blood‑sugar control or health outcomes [2].

ADA’s new guidance on technology in primary care

The ADA released its first scientific statement focused solely on diabetes technology in primary‑care settings [3]. It notes that three‑quarters of U.S. counties lack an endocrinologist, making primary care the main entry point for most people with diabetes [3]. The statement urges that all individuals with diabetes have access to evidence‑based technologies and that primary‑care teams receive clear guidance on how to support their use [3].

Why these pieces matter together

The employer study did not track clinical outcomes [2].